Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis

L.C. Franke, A.J.H.A. Ament, M.A.F.J. van de Laar, A. Boonen, J.L. Severens

Research output: Contribution to journalArticleAcademicpeer-review

87 Citations (Scopus)
124 Downloads (Pure)


OBJECTIVES: To assess, quantify and summarise the cost of illness of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) from the societal perspective.

METHODS: Original studies reporting costs of RA or AS were searched systematically. Both cost-of-illness studies and economic evaluations of therapies were included. Studies were appraised for patient and study characteristics, type of costs and actual costs. Reported costs were aggregated by cost categories and overall mean costs were summarised by cost domain (healthcare, patient and family, and productivity costs).

RESULTS: Overall mean costs of RA (€14,906 per year) were above that of AS (€9,374 per year), while the relative distribution of costs over cost domains was approximately similar. For both diseases, productivity costs based on the human cost approach were 3 to 10 times higher than the friction costs and accounted for more than half the total costs of both diseases.

CONCLUSIONS: Productivity costs constitute the largest part of the total cost-off-illness of RA and AS reflecting the high burden of the disease on work participation. Although total and direct costs of illness in RA were higher than in AS, the average age of AS patients was 10 years lower and therefore, lifetime costs associated with AS may actually be equal or higher.
Original languageEnglish
Article numberCER3653
Pages (from-to)0118-0123
JournalClinical and experimental rheumatology
Issue number4, Suppl. 55
Publication statusPublished - 2009


  • Ankylosing spondylitis
  • Cost-of-illness
  • Costs
  • Rheumatoid arthritis


Dive into the research topics of 'Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis'. Together they form a unique fingerprint.

Cite this